The AIDS epidemic has been a global public health issue for more than 40 years and has
resulted in~ 40 million deaths. AIDS is caused by the retrovirus, HIV-1, which is transmitted …

People with HIV (PWH) are at elevated risk for cardiovascular diseases (CVDs), including
myocardial infarction, heart failure, and sudden cardiac death, among other CVD …

Background Tenofovir alafenamide (TAF) has replaced tenofovir disoproxil fumarate (TDF)
in many clinical settings. However, concerns remain about potential metabolic complications …

Background Lipid‐lowering effect was observed during treatment with tenofovir disoproxil
fumarate (TDF) for chronic hepatitis B (CHB). However, the metabolic features in patients …

Background The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and
other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B …

Introduction Chronic viral replication has been linked to an increased risk of cardiovascular
and metabolic diseases in people living with HIV (PLWH), but few studies have evaluated …

Background While both the burden of therapy and the individual drugs in
bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) and dolutegravir/lamivudine …

Over the past 4 decades, the clinical care of people living with HIV (PLWH) evolved from
treatment of acute opportunistic infections to the management of chronic, noncommunicable …

Background: Bictegravir (BIC), a recently introduced integrase inhibitor, is available in a
single tablet regimen with tenofovir alafenamide (TAF) and emtricitabine (FTC)(BIC-STR) …

Introduction Tenofovir alafenamide (TAF) is approved for paediatric use in fixed‐dose
combination tablets, but efficacy and safety data in children are limited. We conducted a …